A Phase 1 interventional study of Enlicitide Chloride in Moderate Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the safety, tolerability and pharmacokinetic (PK) effects of enlicitide chloride in participants with moderate renal impairment (RI) to those of healthy matched control participants. Moderate RI was defined as the estimated glomerular filtration rate (eGFR) ≥30 and \<60milliliter/minute/1.73meters\^2 (ml/min/1.73m\^2). There is no formal hypothesis.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of enlicitide chloride 10 mg
Drug: Enlicitide Chloride
Single dose of enlicitide chloride 10 mg
Drug: Enlicitide Chloride
10 mg capsule administered orally
Also known as: MK-0616
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of MK-0616
Blood samples were collected at pre-specified timepoints to determine the AUC0-inf of MK-0616. AUC0-inf was defined as the area under the concentration-time curve of MK-0616 from time zero to infinity.
Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Area Under the Concentration- Time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of MK-0616.
Blood samples were collected at pre-specified timepoints to determine the AUC0-last of MK-0616. AUC0-last was defined as the area under the concentration-time curve of MK-0616 from time zero to last measurable concentration.
Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Maximum Plasma Concentration (Cmax) of MK-0616
Blood samples were collected at pre-specified time points to determine the Cmax of MK-0616. Cmax was defined as the maximum concentration of MK-0616 reached.
Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Time to Maximum Plasma Concentration (Tmax) of MK-0616
Blood samples were collected at pre-specified timepoints to determine the Tmax of MK-0616. Tmax was defined as time to the maximum concentration of MK-0616 reached.
Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Apparent Terminal Half-life (t1/2) of MK-0616
Blood samples were collected at pre-specified timepoints to determine the t1/2 of MK-0616. t1/2 was defined as the time required to divide the MK-0616 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-0616.
Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Apparent Clearance (CL/F) of MK-0616
Blood samples were collected at pre-specified timepoints to determine the CL/F of MK-0616. CL/F was the apparent total clearance of MK-0616 in plasma over time, assessed as the rate at which MK-0616 was removed from the plasma.
Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Apparent Volume of Distribution (Vz/F) of MK-0616
Blood samples were collected at pre-specified timepoints to determine the Vz/F of MK-0616. Vz/F was the apparent volume of distribution of MK-0616 between the plasma and the rest of the body, after dose, assessed as the total volume of MK-0616 that would need to be uniformly distributed to achieve the desired plasma drug concentration.
Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.
Time frame: Up to approximately 14 days
Number of Participants Who Discontinued From the Study Due to an AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who discontinued from the study due to an AE were reported.
Time frame: Up to approximately 14 days
Amount Recovered in Urine From 0 to 24 Hours (Ae0-24) of MK-0616
Urine samples were collected at pre-specified time points to determine the AE0-24 of MK-0616. Ae0-24 was defined as the amount of MK-0616 recovered in urine from time 0-24 hours.
Time frame: Predose and at 0, 4, 8, 12 and 24 hours postdose
Fraction of Dose Recovered in Urine (Fe) of MK-0616
Urine samples were collected at pre-specified time points to determine the Fe of MK-0616. Fe was defined as the fraction of dose of MK-0616 recovered in urine.
Time frame: Predose and at 0, 4, 8, 12, 24, 36 and 48 hours postdose
Renal Clearance (CLr) of MK-0616
Urine samples were collected at pre-specified time points to determine the CLr of MK-0616. was defined as the time it takes for the MK-0616 to be completely removed by the kidneys.
Time frame: Predose and 4, 8, 12, 24, 36, and 48 hours postdose
Percent Change From Baseline in Free Proprotein Convertase Subtilisin Kexin 9 (PCSK9)
Urine samples were collected at pre-specified time points (baseline and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 and 336 hours postdose) to evaluate the reduction in free PCSK9 from baseline to up to 336 hours postdose after administration of MK-0616. The percent change from baseline in free PCSK9 was reported.
Time frame: Baseline (Predose) and up to 336 hours post dose
Of 24 participants screened for inclusion, 18 participants were allocated to receive MK-0616 single dose 10-mg. All participants received at least one dose of study intervention.
| Milestone | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Started | 10 | 8 |
| Completed | 10 | 8 |
| Not completed | 0 | 0 |
Blood samples were collected at pre-specified timepoints to determine the AUC0-inf of MK-0616. AUC0-inf was defined as the area under the concentration-time curve of MK-0616 from time zero to infinity.
| hour*nmol/Liter | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of MK-0616 | 453 (211 to 972) | 369 (211 to 646) |
Blood samples were collected at pre-specified timepoints to determine the AUC0-last of MK-0616. AUC0-last was defined as the area under the concentration-time curve of MK-0616 from time zero to last measurable concentration.
| hour*nmol/Liter | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Area Under the Concentration- Time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of MK-0616. | 312 (120 to 815) | 192 (64.1 to 574) |
Blood samples were collected at pre-specified time points to determine the Cmax of MK-0616. Cmax was defined as the maximum concentration of MK-0616 reached.
| nmol/Liter | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of MK-0616 | 5.80 (2.98 to 11.3) | 4.00 (1.97 to 8.13) |
Blood samples were collected at pre-specified timepoints to determine the Tmax of MK-0616. Tmax was defined as time to the maximum concentration of MK-0616 reached.
| Hour | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of MK-0616 | 2.00 (1.00 to 24.00) | 4.66 (1.50 to 24.02) |
Blood samples were collected at pre-specified timepoints to determine the t1/2 of MK-0616. t1/2 was defined as the time required to divide the MK-0616 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-0616.
| Hour | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Apparent Terminal Half-life (t1/2) of MK-0616 | 55.1 ± 44.1 | 48.8 ± 32.0 |
Blood samples were collected at pre-specified timepoints to determine the CL/F of MK-0616. CL/F was the apparent total clearance of MK-0616 in plasma over time, assessed as the rate at which MK-0616 was removed from the plasma.
| Liter/hour | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Apparent Clearance (CL/F) of MK-0616 | 14.2 (6.63 to 30.6) | 17.5 (9.99 to 30.5) |
Blood samples were collected at pre-specified timepoints to determine the Vz/F of MK-0616. Vz/F was the apparent volume of distribution of MK-0616 between the plasma and the rest of the body, after dose, assessed as the total volume of MK-0616 that would need to be uniformly distributed to achieve the desired plasma drug concentration.
| Liter | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Apparent Volume of Distribution (Vz/F) of MK-0616 | 1130 (675 to 1900) | 1230 (972 to 1550) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.
| Participants | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 3 | 2 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who discontinued from the study due to an AE were reported.
| Participants | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Number of Participants Who Discontinued From the Study Due to an AE | 0 | 0 |
Urine samples were collected at pre-specified time points to determine the AE0-24 of MK-0616. Ae0-24 was defined as the amount of MK-0616 recovered in urine from time 0-24 hours.
| Miligram | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Amount Recovered in Urine From 0 to 24 Hours (Ae0-24) of MK-0616 | 0.0116 (0.00288 to 0.0467) | 0.0141 (0.00485 to 0.0409) |
Urine samples were collected at pre-specified time points to determine the Fe of MK-0616. Fe was defined as the fraction of dose of MK-0616 recovered in urine.
| Percent | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Fraction of Dose Recovered in Urine (Fe) of MK-0616 | 0.116 (0.0288 to 0.467) | 0.141 (0.0485 to 0.409) |
Urine samples were collected at pre-specified time points to determine the CLr of MK-0616. was defined as the time it takes for the MK-0616 to be completely removed by the kidneys.
| Liter/hour | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Renal Clearance (CLr) of MK-0616 | 0.0573 (0.0157 to 0.209) | 0.152 (0.0781 to 0.294) |
Urine samples were collected at pre-specified time points (baseline and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 and 336 hours postdose) to evaluate the reduction in free PCSK9 from baseline to up to 336 hours postdose after administration of MK-0616. The percent change from baseline in free PCSK9 was reported.
| Percent Change | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls |
|---|---|---|
| Change from baseline to 1 hour postdose | -80.5 (-83.6 to -36.3) | -66.6 (-73.4 to -10.2) |
| Change from baseline to 1.5 hours postdose | -90.9 (-97.7 to -66.2) | -88.6 (-98.3 to -54.5) |
| Change from baseline to 2 hours postdose | -90.8 (-96.5 to -68.9) | -87.1 (-96.8 to -54.9) |
| Change from baseline to 3 hours postdose | -89.7 (-96.1 to -67.1) | -86.0 (-95.0 to -60.7) |
| Change from baseline to 5 hours postdose | -89.6 (-94.8 to -73.5) | -83.6 (-97.0 to -51.6) |
| Change from baseline to 8 hours postdose | -84.9 (-91.6 to -64.3) | -78.5 (-97.8 to -35.1) |
| Change from baseline to 12 hours postdose | -71.8 (-80.4 to -43.5) | -60.8 (-93.4 to 9.55) |
| Change from baseline to 24 hours postdose | -67.2 (-75.2 to -43.8) | -27.9 (-47.3 to 6.46) |
| Change from baseline to 36 hours postdose | -54.9 (-64.6 to -30.9) | 1.38 (-26.4 to 47.2) |
| Change from baseline to 48 hours postdose | -44.9 (-56.6 to -15.3) | 5.11 (-10.2 to 26.2) |
| Change from baseline to 336 hours postdose | 5.00 (-9.22 to 27.2) | 7.50 (-4.78 to 21.2) |
Collected over Up to approximately 16 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A - Moderate RI | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Panel B - Healthy Controls | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Event | Panel A - Moderate RI | Panel B - Healthy Controls |
|---|---|---|
| PalpitationsCardiac disorders | 0/10 | 1/8 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 1/8 |
| FatigueGeneral disorders | 0/10 | 1/8 |
| HeadacheNervous system disorders | 0/10 | 1/8 |
| Axillary painGeneral disorders | 1/10 | 0/8 |
| HypokalaemiaMetabolism and nutrition disorders | 1/10 | 0/8 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/10 | 0/8 |
| DizzinessNervous system disorders | 1/10 | 0/8 |
All allocated participants.
| Age, Continuous(Years) | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls | Total |
|---|---|---|---|
| Mean | 66.5 ± 5.6 | 60.4 ± 5.0 | 63.8 ± 6.1 |
| Sex: Female, Male(Participants) | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 5 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 5 |
| Not Hispanic or Latino | 9 | 4 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Panel A - Moderate Renal Impairment (RI) | Panel B - Healthy Controls | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 4 | 4 |
| White | 10 | 4 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2021 to primary completion in May 2023, 17 months.
Results were first posted in Sep 2024, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enlicitide chloride